NASDAQ:AMGN - Amgen News Headlines

Sign in or create an account to add this stock to your watchlist.
$202.34 +1.53 (+0.76 %)
(As of 09/18/2018 04:00 PM ET)
Previous Close$200.81
Today's Range$199.20 - $203.87
52-Week Range$163.31 - $204.42
Volume1.98 million shs
Average Volume3.63 million shs
Market Capitalization$129.83 billion
P/E Ratio16.18
Dividend Yield2.63%
Beta1.4

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
FY2018 Earnings Estimate for Amgen, Inc. Issued By Leerink Swann (AMGN)FY2018 Earnings Estimate for Amgen, Inc. Issued By Leerink Swann (AMGN)
www.americanbankingnews.com - September 18 at 7:34 AM
Worlds Largest Alzheimers Survey Reveals Most Adults Believe a Cure Will be Developed in Their LifetimeWorld's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
finance.yahoo.com - September 17 at 5:28 PM
Amgen (AMGN) Given a $209.00 Price Target at Leerink SwannAmgen (AMGN) Given a $209.00 Price Target at Leerink Swann
www.americanbankingnews.com - September 17 at 12:03 PM
Is Now a Good Time to Buy Amgen?Is Now a Good Time to Buy Amgen?
www.fool.com - September 15 at 9:11 AM
Is Amgen (AMGN) a Great Stock for Value Investors?Is Amgen (AMGN) a Great Stock for Value Investors?
www.msn.com - September 14 at 5:12 PM
Amgens (AMGN) Management on BofAML Global Health Conference 2018 - TranscriptAmgen's (AMGN) Management on BofAML Global Health Conference 2018 - Transcript
seekingalpha.com - September 14 at 5:12 PM
Why Amgen Will Likely Be a Boring Dividend Stock Over the Next Few YearsWhy Amgen Will Likely Be a Boring Dividend Stock Over the Next Few Years
finance.yahoo.com - September 13 at 8:05 AM
$5.76 Billion in Sales Expected for Amgen, Inc. (AMGN) This Quarter$5.76 Billion in Sales Expected for Amgen, Inc. (AMGN) This Quarter
www.americanbankingnews.com - September 13 at 3:58 AM
Amgens (AMGN) CEO Bob Bradway on Morgan Stanley Healthcare Conference - TranscriptAmgen's (AMGN) CEO Bob Bradway on Morgan Stanley Healthcare Conference - Transcript
seekingalpha.com - September 12 at 5:01 PM
Amgen (AMGN) Given a $220.00 Price Target at Jefferies Financial GroupAmgen (AMGN) Given a $220.00 Price Target at Jefferies Financial Group
www.americanbankingnews.com - September 12 at 10:42 AM
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare ConferenceAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
finance.yahoo.com - September 11 at 5:04 PM
Amgen, Inc. (AMGN) Expected to Post Earnings of $3.38 Per ShareAmgen, Inc. (AMGN) Expected to Post Earnings of $3.38 Per Share
www.americanbankingnews.com - September 11 at 10:52 AM
Amgen Looks To Enter Multiple Myeloma Space: Can It Compete?Amgen Looks To Enter Multiple Myeloma Space: Can It Compete?
seekingalpha.com - September 11 at 8:02 AM
Amgens Aimovig Launch Looks Strong; Monitor Biosimilar DevelopmentsAmgen's Aimovig Launch Looks Strong; Monitor Biosimilar Developments
seekingalpha.com - September 11 at 8:02 AM
Recent AMGN NewsRecent AMGN News
www.bloomberg.com - September 10 at 5:07 PM
Amgen (AMGN) Given a $193.00 Price Target by Royal Bank of Canada AnalystsAmgen (AMGN) Given a $193.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - September 10 at 12:08 PM
Amgen (AMGN) Given a $224.00 Price Target at OppenheimerAmgen (AMGN) Given a $224.00 Price Target at Oppenheimer
www.americanbankingnews.com - September 10 at 10:44 AM
Amgen To Present At The Morgan Stanley Global Healthcare ConferenceAmgen To Present At The Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 7 at 5:17 PM
AstraZeneca, Amgen Announce Breakthrough Therapy Designation For TezepelumabAstraZeneca, Amgen Announce Breakthrough Therapy Designation For Tezepelumab
www.nasdaq.com - September 7 at 8:03 AM
AstraZeneca gets FDA breakthrough therapy label for asthma treatmentAstraZeneca gets FDA breakthrough therapy label for asthma treatment
finance.yahoo.com - September 7 at 8:03 AM
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic PhenotypeTezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
finance.yahoo.com - September 7 at 8:03 AM
Hospital groups launch own company to make generic drugsHospital groups launch own company to make generic drugs
marketbeat.com - September 6 at 12:18 AM
[$$] Biotech Veterans Raise $320 Million for New Life Sciences Venture Fund[$$] Biotech Veterans Raise $320 Million for New Life Sciences Venture Fund
finance.yahoo.com - September 5 at 5:19 PM
Better Buy: Amgen Inc. vs. Gilead Sciences, Inc.Better Buy: Amgen Inc. vs. Gilead Sciences, Inc.
finance.yahoo.com - September 2 at 8:01 AM
Amgens Leukemia Drug Blincyto Gets EU Nod for Pediatric UseAmgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use
finance.yahoo.com - August 30 at 5:37 PM
Expanded use of Amgens Blincyto OKd in EuropeExpanded use of Amgen's Blincyto OK'd in Europe
seekingalpha.com - August 29 at 5:11 PM
Amgen (AMGN) Says EC Approves BLINCYTO For Use In Pediatric Patients With Philadelphia Chromosome-Negative R/R B-Cell Precursor ALLAmgen (AMGN) Says EC Approves BLINCYTO For Use In Pediatric Patients With Philadelphia Chromosome-Negative R/R B-Cell Precursor ALL
www.streetinsider.com - August 29 at 5:11 PM
Amgen (AMGN) PT Set at $197.00 by Wells Fargo & CoAmgen (AMGN) PT Set at $197.00 by Wells Fargo & Co
www.americanbankingnews.com - August 29 at 10:46 AM
Amgen Seeks US Approval for Its KYPROLIS in a Combo for Multiple MyelomaAmgen Seeks US Approval for Its KYPROLIS in a Combo for Multiple Myeloma
finance.yahoo.com - August 28 at 5:08 PM
Oppenheimer Reiterates $224.00 Price Target for Amgen (AMGN)Oppenheimer Reiterates $224.00 Price Target for Amgen (AMGN)
www.americanbankingnews.com - August 28 at 11:27 AM
Amgen files U.S. marketing application for weekly regimen of KyprolisAmgen files U.S. marketing application for weekly regimen of Kyprolis
seekingalpha.com - August 27 at 5:23 PM
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With DexamethasoneAmgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
www.bizjournals.com - August 27 at 5:23 PM
Amgen Submits SNDA For KYPROLIS - Quick FactsAmgen Submits SNDA For KYPROLIS - Quick Facts
www.nasdaq.com - August 27 at 5:23 PM
Why Is Amgen (AMGN) Up 1.3% Since Last Earnings Report?Why Is Amgen (AMGN) Up 1.3% Since Last Earnings Report?
finance.yahoo.com - August 27 at 9:13 AM
Amgen, Inc. (AMGN) Receives Average Recommendation of "Hold" from AnalystsAmgen, Inc. (AMGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 26 at 2:38 AM
Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple MyelomaYour Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma
seekingalpha.com - August 24 at 5:20 PM
3 Big Drug Stocks With Big Cash Stockpiles: Should You Spend Your Cash Buying Them?3 Big Drug Stocks With Big Cash Stockpiles: Should You Spend Your Cash Buying Them?
finance.yahoo.com - August 24 at 5:20 PM
Amgen (AMGN) PT Set at $220.00 by Jefferies Financial GroupAmgen (AMGN) PT Set at $220.00 by Jefferies Financial Group
www.americanbankingnews.com - August 24 at 1:44 PM
Own A Bond Instead Of Ford - Cramers Lightning Round (8/22/18)Own A Bond Instead Of Ford - Cramer's Lightning Round (8/22/18)
seekingalpha.com - August 23 at 8:04 AM
Cramer's lightning round: Pick this stock for a biotech p...Cramer's lightning round: Pick this stock for a biotech p...
finance.yahoo.com - August 23 at 8:04 AM
Trade of the Day: Amgen Is a Strong Stock in a Giddy IndustryTrade of the Day: Amgen Is a Strong Stock in a Giddy Industry
investorplace.com - August 23 at 7:42 AM
Is Amgen Inc. a Buy?Is Amgen Inc. a Buy?
www.fool.com - August 22 at 6:54 AM
Brokers Offer Predictions for Amgen, Inc.s Q3 2018 Earnings (AMGN)Brokers Offer Predictions for Amgen, Inc.'s Q3 2018 Earnings (AMGN)
www.americanbankingnews.com - August 22 at 5:49 AM
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018
finance.yahoo.com - August 21 at 8:03 AM
Recent Developments for Amgen since Q2 2018Recent Developments for Amgen since Q2 2018
finance.yahoo.com - August 21 at 8:03 AM
Amgen’s Product Performance in Q2 2018Amgen’s Product Performance in Q2 2018
finance.yahoo.com - August 21 at 8:03 AM
FY2019 EPS Estimates for Amgen, Inc. (AMGN) Lifted by AnalystFY2019 EPS Estimates for Amgen, Inc. (AMGN) Lifted by Analyst
www.americanbankingnews.com - August 21 at 7:23 AM
Amgen Stock Up This Year So Far: Will the Rally Continue?Amgen Stock Up This Year So Far: Will the Rally Continue?
www.zacks.com - August 20 at 9:15 AM
[$$] Gormleys Take: Cancer-Killing Viruses Catch On With VCs[$$] Gormley's Take: Cancer-Killing Viruses Catch On With VCs
finance.yahoo.com - August 17 at 8:10 AM
Amgen: Cramer Discusses the AAP Portfolios New EditionAmgen: Cramer Discusses the AAP Portfolio's New Edition
finance.yahoo.com - August 15 at 5:37 PM
This page was last updated on 9/18/2018 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel